Daiwa: Citing Sino Biopharmaceutical (01177.HK) management reiterating this year's double-digit revenue growth guidance, rating "Buy"

Zhito Finance APP has learned that Daiwa released a research report stating that at a recent healthcare industry exchange event, the management of Sino Biopharmaceutical (01177.HK) reiterated that its guidance for double-digit year-on-year revenue growth this year remains unchanged, expected to be driven jointly by licensing revenue and growth in innovative drug sales, and anticipated that innovative drug sales plus licensing revenue will contribute half of full-year revenue. Daiwa currently rates Sino Biopharmaceutical as "Buy."